Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model

Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment

(2018) M. Garofalo et al.   JOURNAL OF CONTROLLED RELEASE

Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model

(2018) Lukasz Kuryk et al.   JOURNAL OF MEDICAL VIROLOGY

TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade

(2018) V. Cervera-Carrascon et al.   OncoImmunology

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

(2017) Jacob Schachter et al.   LANCET

Advances in Immunotherapy for Melanoma: A Comprehensive Review

(2017) Carmen Rodríguez-Cerdeira et al.   MEDIATORS OF INFLAMMATION

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma

(2017) Cristian Capasso et al.   OncoImmunology

Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy

(2017) Sadia Zafar et al.   OncoImmunology

Immune System, Friend or Foe of Oncolytic Virotherapy?

(2017) Anna C. Filley et al.   Frontiers in Oncology

Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 – Support for clinical studies on advanced cancer treatment

(2017) Lukasz Kuryk et al.   PLoS One

Advances in immunotherapy for melanoma

(2016) Jason M. Redman et al.   BMC Medicine

Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model

(2016) Lukasz Kuryk et al.   INTERNATIONAL JOURNAL OF CANCER

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

(2016) Antoni Ribas et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

(2016) Adil I. Daud et al.   JOURNAL OF CLINICAL ONCOLOGY

Oncolytic Adenovirus Loaded with L-carnosine as Novel Strategy to Enhance the Antitumor Activity

(2016) M. Garofalo et al.   MOLECULAR CANCER THERAPEUTICS

Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity

(2016) Mari Hirvinen et al.   Molecular Therapy-Oncolytics

Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers

(2016) Tuuli Ranki et al.   Journal for ImmunoTherapy of Cancer

Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Resultsin vitro, in rodents and in humans

(2015) Simona Bramante et al.   INTERNATIONAL JOURNAL OF CANCER

Immunological data from cancer patients treated with Ad5/3 E2F Δ24 GMCSF suggests utility for tumor immunotherapy

(2015) Otto Hemminki et al.   Oncotarget

Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment

(2015) Kirsten Ridder et al.   OncoImmunology

Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma

(2015) Cristian Capasso et al.   OncoImmunology

Innate Immunity to Adenovirus

(2014) Rodinde Hendrickx et al.   HUMAN GENE THERAPY

Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF-Coding Oncolytic Adenovirus

(2013) A. Kanerva et al.   CLINICAL CANCER RESEARCH

Humanized mice: novel model for studying mechanisms of human immune-based therapies

(2013) Louis Gonzalez et al.   IMMUNOLOGIC RESEARCH

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

(2013) Charles G. Drake et al.   Nature Reviews Clinical Oncology

Immunogenic Cell Death in Cancer Therapy

(2012) Guido Kroemer et al.   Annual Review of Immunology

T Cell Receptors are Structures Capable of Initiating Signaling in the Absence of Large Conformational Rearrangements

(2012) Ricardo A. Fernandes et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Oncolytic adenoviruses

(2012) Vincenzo Cerullo et al.   OncoImmunology

Discrimination between primary necrosis and apoptosis by necrostatin-1 in Annexin V-positive/propidium iodide-negative cells

(2011) Hirofumi Sawai et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy

(2011) Yuting Ma et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF

(2010) Anniina Koski et al.   MOLECULAR THERAPY

Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14

(2010) Hongjie Wang et al.   NATURE MEDICINE

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA